Hepatocellular carcinoma: Advances in systemic therapies [version 2; peer review: 2 approved, 1 approved with reservations]

Advanced hepatocellular carcinoma (HCC) is traditionally associated with limited treatment options and a poor prognosis. Sorafenib, a multiple tyrosine kinase inhibitor, was introduced in 2007 as a first-in-class systemic agent for advanced HCC. After sorafenib, a range of targeted therapies and imm...

Full description

Bibliographic Details
Published in:F1000Research
Main Authors: Lung-Yi Mak, Man-Fung Yuen, Wai-Kay Seto, James Fung, Rex Wan-Hin Hui, Trevor Kwan-Hung Wu
Format: Article
Language:English
Published: F1000 Research Ltd 2024-05-01
Subjects:
HCC
Systemic therapy
TKI
ICI
Liver
Neoadjuvant
eng
Online Access:https://f1000research.com/articles/13-104/v2

Internet

https://f1000research.com/articles/13-104/v2

Similar Items